Split History
ETFs Holding CYTK »    CYTK Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor. According to our CYTK split history records, Cytokinetics has had 1 split.
CYTK split history picture
Cytokinetics (CYTK) has 1 split in our CYTK split history database. The split for CYTK took place on June 25, 2013. This was a 1 for 6 reverse split, meaning for each 6 shares of CYTK owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as Cytokinetics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the CYTK split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cytokinetics shares, starting with a $10,000 purchase of CYTK, presented on a split-history-adjusted basis factoring in the complete CYTK split history. CYTK split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/01/2012
End date: 09/27/2022
Start price/share: $5.16
End price/share: $49.23
Dividends collected/share: $0.00
Total return: 854.07%
Average Annual Total Return: 25.32%
Starting investment: $10,000.00
Ending investment: $95,426.01
Years: 9.99
Date Ratio
06/25/20131 for 6
CYTK is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CYTR Split History
CYTX Split History
DARA Split History
DCTH Split History
DFFN Split History
DGX Split History
DHR Split History
DMPI Split History
DRAD Split History
DSCI Split History

Also explore: CYTK shares outstanding history

Email EnvelopeFree CYTK Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
TD Holdings, Inc. (GLG )
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CYTK Insider Buying

CYTK Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.